CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...